HRP20080569T3 - Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin - Google Patents

Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin

Info

Publication number
HRP20080569T3
HRP20080569T3 HR20080569T HRP20080569T HRP20080569T3 HR P20080569 T3 HRP20080569 T3 HR P20080569T3 HR 20080569 T HR20080569 T HR 20080569T HR P20080569 T HRP20080569 T HR P20080569T HR P20080569 T3 HRP20080569 T3 HR P20080569T3
Authority
HR
Croatia
Prior art keywords
deazaaminopterin
propargyl
cell lymphoma
treatment
formulation
Prior art date
Application number
HR20080569T
Other languages
English (en)
Croatian (hr)
Inventor
A. O'connor Owen
Sirotnak Francis
Original Assignee
Sloan-Kettering Institute For Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34971703&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20080569(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sloan-Kettering Institute For Cancer Research filed Critical Sloan-Kettering Institute For Cancer Research
Publication of HRP20080569T3 publication Critical patent/HRP20080569T3/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HR20080569T 2004-05-30 2005-05-31 Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin HRP20080569T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52159304P 2004-05-30 2004-05-30
PCT/US2005/019169 WO2005117891A1 (en) 2004-05-30 2005-05-31 Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin

Publications (1)

Publication Number Publication Date
HRP20080569T3 true HRP20080569T3 (en) 2008-12-31

Family

ID=34971703

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20080569T HRP20080569T3 (en) 2004-05-30 2005-05-31 Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin

Country Status (23)

Country Link
US (4) US7939530B2 (https=)
EP (1) EP1750716B1 (https=)
JP (1) JP5005532B2 (https=)
KR (1) KR101189693B1 (https=)
CN (2) CN102824346B (https=)
AT (1) ATE405272T1 (https=)
AU (1) AU2005249516B2 (https=)
BR (1) BRPI0510895A (https=)
CA (1) CA2565968C (https=)
DE (1) DE602005009176D1 (https=)
DK (1) DK1750716T3 (https=)
ES (1) ES2313365T3 (https=)
HR (1) HRP20080569T3 (https=)
ME (1) ME01087B (https=)
MX (1) MXPA06013559A (https=)
NO (1) NO337276B1 (https=)
NZ (2) NZ576849A (https=)
PL (1) PL1750716T3 (https=)
PT (1) PT1750716E (https=)
RS (1) RS50622B (https=)
SI (1) SI1750716T1 (https=)
WO (2) WO2005117891A1 (https=)
ZA (1) ZA200609266B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
US8263354B2 (en) * 2004-05-30 2012-09-11 Sloan-Kettering Institute For Cancer Research Methods for assessing cancer for increased sensitivity to 10-propargyl-10-deazaaminopterin
US20080188479A1 (en) * 2004-05-30 2008-08-07 Sloan-Kettering Institute For Cancer Research Methods to Treat Cancer with 10-propargyl-10-deazaaminopterin and Methods for Assessing Cancer for Increased Sensitivity to 10-propargyl-10-deazaaminopterin
CA2565968C (en) 2004-05-30 2013-01-08 Sloan-Kettering Institute For Cancer Research Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin
KR101335021B1 (ko) 2007-07-31 2013-12-12 액세라인크 게놈 테스트의 용도 및 인지 기능 저하 치료용 케톤성 화합물
US20100248249A1 (en) * 2007-08-17 2010-09-30 Allos Therapeutics, Inc. Methods for Assessing Cancer for Increased Sensitivity to 10-Propargyl-10-Deazaaminopterin by Assessing Egfr Levels
US9901578B2 (en) 2007-08-17 2018-02-27 Allos Therapeutics, Inc. Combination of 10-propargyl-10-deazaaminopterin and erlotinib for the treatment of non-small cell lung cancer
WO2009026234A1 (en) * 2007-08-17 2009-02-26 Allos Therapeutics, Inc. Combination of 10-propargyl-10-deazaaminopterin and erlotinib for the treatment of non-small cell lung cancer
US9125881B2 (en) 2008-07-03 2015-09-08 Accera, Inc. Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
WO2010022277A2 (en) * 2008-08-20 2010-02-25 O'connor Owen A Combination of 10-propargyl-10-deazaaminopterin and bortezomib for the treatment of cancers
US20110190305A1 (en) 2010-02-02 2011-08-04 Allos Therapeutics, Inc. Optically Pure Diastereomers of 10-Propargyl-10-Deazaaminopterin and Methods of Using Same
EP2575466B1 (en) * 2010-06-02 2015-04-08 Allos Therapeutics, Inc. Methods for treating methotrexate-resistant disorders with 10-propargyl-10-deazaaminopterin
US20130178441A1 (en) * 2010-08-10 2013-07-11 Allos Therapeutics, Inc. Methods for Extending Progression-Free Survival using 10-Propargyl-10-Deazaaminopterin
WO2013164856A1 (en) 2012-05-04 2013-11-07 Avra Laboratories Private Limited A process for preparing intermediates of 10-propargyl-10-deazaaminopterin (pralatrexate) synthesis and the intermediates thereof
CN103274943B (zh) * 2013-05-24 2015-01-21 苏州明锐医药科技有限公司 4-[1-(2-丙炔基)-3,4-二氧代正丁基]苯甲酸酯及其制备方法
WO2016205203A1 (en) 2015-06-16 2016-12-22 Spectrum Pharmaceuticals, Inc. Combination therapy using belinostat and pralatrexate to treat lymphoma

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4393064A (en) * 1976-03-05 1983-07-12 Sri International Process and composition for treatment of leukemia and process for preparing the same
US4652533A (en) * 1983-04-28 1987-03-24 Pandex Laboratories, Inc. Method of solid phase immunoassay incorporating a luminescent label
US4843155A (en) * 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
DE69133095T2 (de) * 1990-11-20 2003-03-27 Dade Behring Marburg Gmbh Cyclosporin-Immunoassay
US5354751A (en) * 1992-03-03 1994-10-11 Sri International Heteroaroyl 10-deazaamino-pterine compounds and use for rheumatoid arthritis
US5981592A (en) * 1995-03-13 1999-11-09 Loma Linda University Medical Center Method and composition for treating cystic fibrosis
US6323205B1 (en) * 1996-07-17 2001-11-27 Sloan-Kettering Institute For Cancer Research Combinations of 10-propargyl-10-deazaaminopterin and taxols and methods of using same in the treatment of tumors
PT944389E (pt) * 1996-07-17 2008-12-03 Sloan Kettering Inst Cancer Composições purificadas de 10-propargil-10-desaza-aminopterina e métodos para a sua utilização no tratamento de tumores
GB0128510D0 (en) * 2001-11-28 2002-01-23 Novartis Ag Organic compounds
CA2565968C (en) * 2004-05-30 2013-01-08 Sloan-Kettering Institute For Cancer Research Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin

Also Published As

Publication number Publication date
US8299078B2 (en) 2012-10-30
RS50622B (sr) 2010-06-30
KR20110081327A (ko) 2011-07-13
WO2005117892A1 (en) 2005-12-15
CN102824346B (zh) 2015-04-22
BRPI0510895A (pt) 2007-11-27
CA2565968A1 (en) 2005-12-15
MXPA06013559A (es) 2007-04-24
US7939530B2 (en) 2011-05-10
AU2005249516A1 (en) 2005-12-15
EP1750716A1 (en) 2007-02-14
EP1750716B1 (en) 2008-08-20
KR101189693B1 (ko) 2012-10-10
CN102824346A (zh) 2012-12-19
WO2005117891A1 (en) 2005-12-15
SI1750716T1 (sl) 2009-06-30
PL1750716T3 (pl) 2009-01-30
US20080058280A1 (en) 2008-03-06
DK1750716T3 (da) 2008-12-08
JP5005532B2 (ja) 2012-08-22
NO337276B1 (no) 2016-02-29
US20100120777A1 (en) 2010-05-13
DE602005009176D1 (de) 2008-10-02
CA2565968C (en) 2013-01-08
AU2005249516B2 (en) 2010-11-18
NZ576849A (en) 2011-03-31
NZ551082A (en) 2009-06-26
ME01087B (me) 2012-12-20
ES2313365T3 (es) 2009-03-01
NO20065971L (no) 2006-12-22
US20050267117A1 (en) 2005-12-01
ZA200609266B (en) 2008-12-31
US20130053391A1 (en) 2013-02-28
CN1960734A (zh) 2007-05-09
ATE405272T1 (de) 2008-09-15
HK1177901A1 (en) 2013-08-30
PT1750716E (pt) 2008-11-04
US7622470B2 (en) 2009-11-24
JP2008501038A (ja) 2008-01-17

Similar Documents

Publication Publication Date Title
HRP20080569T3 (en) Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin
HRP20070374T3 (en) Formulations comprising ecteinascidin and a disaccharide
TW200637522A (en) Skin treatment articles and methods
PL1654253T3 (pl) Podstawione pochodne 3-pirolidynoindolu
NO20071271L (no) Aryl-substituerte polyakryliske aminer, fremgangsmate for fremstilling av disse og anvendelse som et medikament.
ECSP056229A (es) Una composición farmacéutica que comprende formas polimórficas de 3-(4-amino-1-oxo-1.3 dyhidro-isoindol-2-il)-piperidina-2,6-diona para el tratamiento y manejo de cánceres
HUS1500018I1 (hu) A Bruton-féle tirozin-kináz inhibitorai
TW200605870A (en) Topical methadone compositions and methods for using the same
MX2010006840A (es) Aparato y métodos para suministrar agentes terapeuticos.
ATE412387T1 (de) Medizinische vorrichtungen
ATE461217T1 (de) Glp-1-verbindungen
NO20073026L (no) 2-alkoksy-3,4,5-trihydroksy-alkylamider, fremstilling og sammensetninger derav samt anvendelse derav
DE60327103D1 (de) Darreichungsformen enthaltend einen protonpumphemmer, einen nsaid und einen puffer
AR052774A1 (es) Inmunoterapia para trastornos autoinmunes
NO20091955L (no) Antivirale sammensetninger, og fremgangsmater for anvendelse
UY30308A1 (es) Moduladores de mglur5 v
BRPI0513178A (pt) composições para distribuir fármacos altamente solúveis em água
NO20092690L (no) Aminderivater og deres anvendelse i beta-2-adrenoreseptormedierte sykdommer
CY1108599T1 (el) Η απλιδινη στην αντιμετωπιση του πολλαπλου μυελωματος
DE60142913D1 (de) Arzneilösungen enthaltend modafinilverbindungen
GEP20094801B (en) Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
SE0301650D0 (sv) Novel compounds
TW200716088A (en) Formulations and methods for treating amyloidosis
CL2007001910A1 (es) Compuestos derivados de penem; composicion farmaceutica; y uso en el tratamiento de una infeccion bacteriana.
MXPA05010388A (es) Dispositivos, metodos y composiciones para prevenir la restenosis.